ADVANCE-1, the study that failed, used 30mg qD of subcutaneous Lovenox Lovenox was injected SQ 30mg BID (not QD) in that study: http://clinicaltrials.gov/ct2/show/NCT00097357?term=NCT00097357&rank=1